Therapeutic or Preventive Procedure – Talk Bio

Actionable Insights Powered by AI

Novo Offloads Cell Therapy Technologies to Aspect After Retreat from the Field

5 days ago talkbio0Tagged Aspect - Kind of quantity, Cell Therapy, Diabetes Mellitus, Insulin-Dependent, Hypoimmune Technology, Novo Nordisk, stem cell-derived islet cells

Novo Nordisk; Aspect; cell therapy; type 1 diabetes; stem cell-derived islet cells; hypoimmune technology

Court Rejects HHS Motion to Dismiss Lawsuit Over US Childhood Vaccine Overhaul as Clinician Groups Push Forward

5 days ago talkbio0Tagged ACIP, antiarrhythmic peptide, Centers for Disease Control and Prevention (U.S.), CHARGE Syndrome, Childhood, Immunization Schedule, lawsuit, RFK gene, vaccine overhaul

childhood vaccine overhaul; HHS; lawsuit; ACIP; AAP; CDC; RFK Jr.; immunization schedule

GSK Acquires RAPT Therapeutics for $2.2 Billion to Advance Food Allergy Drug Ozureprubart

6 days ago talkbio0Tagged Acquisition, anti-IgE, Food Allergy, Immunology, ozureprubart, RAPT, SmithKline Beecham

GSK; RAPT Therapeutics; acquisition; $2.2B; ozureprubart; food allergy; anti-IgE; immunology

AstraZeneca Acquires Complete Global Rights to AbelZeta’s C-CAR031 CAR-T Therapy for Up to $630 Million

6 days ago talkbio0Tagged AbelZeta, altretamine/cisplatin/cyclophosphamide protocol, AstraZeneca, C-CAR031, CAR-T, China, GPC3 protein, human, Liver carcinoma

AstraZeneca; AbelZeta; C-CAR031; CAR-T; GPC3; China rights; $630M; hepatocellular carcinoma; HCC

AAVantgarde Completes Enrollment in LUCE-1 Phase 1/2 Trial of AAVB-081 for Usher Syndrome Type 1B-Associated Retinitis Pigmentosa

6 days ago talkbio0Tagged AAVantgarde, AAVB-081, Clinical Trials, gene therapy, LUCE-1, MYO7A gene, Retinitis Pigmentosa, Usher Syndrome Type 1B

AAVantgarde; LUCE-1; AAVB-081; Usher Syndrome Type 1B; USH1B; retinitis pigmentosa; gene therapy; clinical trial

Bayer and Vanderbilt University Medical Center Announce Five-Year Collaboration to Advance Cardiovascular and Kidney Disease Treatments

6 days ago talkbio0Tagged Bayer, BioVU, Cardiovascular Diseases, Collaboration, Kidney Diseases, Precision Medicine, Vanderbilt University Medical Center

Bayer; Vanderbilt University Medical Center; cardiovascular diseases; kidney diseases; collaboration; precision medicine; BioVU

2026 IPO Train Keeps Chugging as AgomAb Therapeutics and SpyGlass Pharma File for Nasdaq Debuts

7 days ago talkbio0Tagged AgomAb, bimatoprost IOL, Biotech IPOs, IPO, Nasdaq, ontunisertib, SpyGlass Pharma (

AgomAb Therapeutics; SpyGlass Pharma; IPO; Nasdaq; 2026 biotech IPOs; ontunisertib; bimatoprost IOL

FW In Conversation: Mineralys CEO Jon Congleton on Reviving Hypertension Innovation and Lorundrostat’s Best-in-Class Potential

7 days ago talkbio0Tagged aldosterone synthase inhibitor, conversation, For which was done, Hypertensive disease, Jon Congleton, Lorundrostat, Mineralys

Mineralys Therapeutics; Jon Congleton; lorundrostat; aldosterone synthase inhibitor; hypertension treatment; FW In Conversation

FDA Announces Flexible Manufacturing Approach for Cell and Gene Therapies on January 11, 2026

2 weeks ago talkbio0Tagged calcium glucarate, Candidiasis, Chronic Mucocutaneous, Cells, gene therapy, Manufacturing, Pliability, requirements, United States Food and Drug Administration

FDA; cell and gene therapies; CGT; manufacturing flexibility; CMC requirements; Marty Makary

Eikon Therapeutics Files for IPO Amid Biotech Rally Test

2 weeks ago talkbio0Tagged cancer drugs, Eikon, File (record), IPO, Nasdaq EIKN, rally

Eikon Therapeutics; IPO filing; biotech rally; cancer drugs; Nasdaq EIKN